Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021

SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-06-02 08:00 2709

Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021

SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-06-02 08:00 2361

Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, May 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-05-28 08:00 2644

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

SHANGHAI and HARTFORD, Conn., May 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengen...

2021-05-25 08:00 2553

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limite...

2021-05-17 20:35 3222

Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial

SHANGHAI and HONG KONG, May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-05-17 08:00 2469

Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China

SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-05-14 08:40 2858

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Today, Antengene Corporation Limited ("Antenge...

2021-05-14 08:00 3722

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer

SHANGHAI and HONG KONG, May 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-05-13 08:00 2610

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

SHANGHAI and HONG KONG, May 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEH...

2021-05-06 11:28 2807

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

SHANGHAI and HONG KONG, April 29, 2021 /PRNewswire/ -- With the official release and implementation...

2021-04-29 08:34 2888

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL

SHANGHAI, China and GAITHERSBURG, U.S., April 13, 2021 /PRNewswire/ -- Antengene Corporation Limite...

2021-04-13 08:00 2862

Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL

Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations

SHANGHAI and HONG KONG, April 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2021-04-12 08:00 2440

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma

SHANGHAI and HONG KONG, April 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-04-06 08:00 8052

Antengene Announces Financial Results for Full Year 2020

SHANGHAI and HONG KONG, March 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" o...

2021-03-26 08:00 3333

Antengene Appoints Kevin Lynch as Chief Medical Officer

SHANGHAI, China and MELBOURNE, Australia, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limi...

2021-03-25 23:26 3050

Antengene Appoints Kevin Lynch as Chief Medical Officer

Antengene Appoints Bo Shan as Chief Scientific Officer

SHANGHAI, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK)...

2021-03-25 22:36 3201

Antengene Appoints Bo Shan as Chief Scientific Officer

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

SHANGHAI and GAITHERSBURG, Md., March 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Ante...

2021-03-22 08:00 2525

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

Antengene Included in the Shenzhen-Hong Kong Stock Connect

SHANGHAI and HONG KONG, March 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene",...

2021-03-15 09:40 2984

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

SHANGHAI and SEOUL, South Korea, March 15, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Ant...

2021-03-15 08:00 3323